Januvia and Ozempic Together: Why Doctors Usually Stop the Januvia

Usually not, and the reason is waste, not danger. Januvia (sitagliptin) and Ozempic (semaglutide) both act on the same GLP‑1 hormone system. The 2026 American Diabetes Association Standards of Care say that taking a DPP‑4 inhibitor such as Januvia with a GLP‑1 or with tirzepatide (Mounjaro) “is not recommended,” because it lowers blood sugar no further than the GLP‑1 does alone. No FDA label forbids the pairing, and none warns of a harmful interaction. In practice, the Januvia usually stops when the GLP‑1 starts. In trials that compared the two drugs directly, the GLP‑1 lowered A1C more and took off 2 to 4 kg more weight.

Why the two drugs overlap

After a meal, the gut releases GLP‑1 and a second hormone, GIP. Both tell the pancreas to release insulin and hold back glucagon when blood sugar is high. An enzyme called DPP‑4 breaks both hormones down quickly. Januvia blocks that enzyme. Its label says that by “increasing and prolonging active incretin levels,” sitagliptin raises insulin release and lowers glucagon.^[2] The other DPP‑4 inhibitors, linagliptin (Tradjenta), alogliptin (Nesina) and saxagliptin, work the same way.^[7]

A GLP‑1 drug takes a more direct route. Instead of protecting the body’s own hormone, it is a long-lasting copy of it, built to resist the enzyme. Ozempic’s label states that semaglutide “is stabilized against degradation by the DPP‑4 enzyme.”^[3] On top of a GLP‑1, Januvia has little left to do: the receptor it would help stimulate is already being driven by the drug.

A small German trial tested exactly that. Sixteen people already on metformin and liraglutide (Victoza) took a single dose of sitagliptin or placebo before a test meal. Sitagliptin did what it is supposed to do at the hormone level, raising intact GLP‑1 by 78% and GIP by 90%. Blood sugar after the meal did not move: the area under the glucose curve was 315 with sitagliptin and 319 with placebo, along with no change in insulin or glucagon. The authors concluded that the GLP‑1 receptors “have probably been maximally stimulated” by liraglutide.^[9]

What the guidelines and labels say

The ADA puts it in a numbered recommendation in its 2026 pharmacology chapter:^[1]

Concurrent use of dipeptidyl peptidase 4 (DPP-4) inhibitors with a GLP-1 RA or a dual GIP and GLP-1 RA is not recommended due to lack of additional glucose lowering beyond that of a GLP-1–based therapy.

— ADA Standards of Care in Diabetes—2026, recommendation 9.18 (grade B)

“Dual GIP and GLP‑1 RA” means tirzepatide, sold as Mounjaro and Zepbound, so the recommendation covers it too. The same chapter rates DPP‑4 inhibitors as having intermediate glucose-lowering power and a neutral effect on weight. It rates GLP‑1 drugs as high to very high on glucose and as causing weight loss.^[1] Elsewhere it says DPP‑4 inhibitors “should be limited or discontinued” when insulin is intensified, because they add nothing for the heart, kidneys, weight or liver.^[1]

The FDA labels are quieter than many websites suggest. Several online answers say the Ozempic label tells patients not to combine it with a DPP‑4 inhibitor. The current label does not. It mentions DPP‑4 only as the enzyme semaglutide resists and sitagliptin only as the comparison drug in one trial.^[3] The Januvia, Janumet and Tradjenta labels do not mention GLP‑1 drugs at all.^[2][6][7] Neither do the Mounjaro and Zepbound labels mention DPP‑4 inhibitors.^[4][22] The co-use warning on the Wegovy label is about a different pairing: two GLP‑1 drugs, or two semaglutide products, at once.^[5] Doubling up on GLP‑1s is covered in switching between GLP-1 drugs.

The few trials that combined them

No large, long trial has tested a DPP‑4 inhibitor added to a weekly GLP‑1 such as Ozempic, Trulicity or Mounjaro. The ADA bases its recommendation on three small studies,^[1] and they do not all point the same way.

The Violante trial is the one result in favor of keeping both. People whose diabetes was not controlled on sitagliptin and metformin were given twice-daily exenatide (Byetta). Those who kept sitagliptin lowered A1C by 0.68 points against 0.38 for those who stopped it, and more of them reached an A1C under 7%: 41.7% against 26.6%.^[10] Exenatide twice daily is short-acting, though. Its effect fades between injections, which may leave room for a DPP‑4 inhibitor that today’s weekly drugs do not. The trial was funded by the drug’s makers, and it lasted 20 weeks. The ADA cites it among the studies behind its recommendation against the pairing.^[1]

The clinic case series is closer to how the combination turns up in real life: a weekly GLP‑1 added while the DPP‑4 stayed on the list. A1C fell 0.8 points and weight barely moved, and none of the 18 patients reached an A1C under 7%. The authors judged the result no better than either drug alone.^[11] It is a small chart review with no control group, so it shows what happened, not why.

Januvia vs Ozempic: the head-to-head trials

This is where the evidence is strongest. Sitagliptin was the comparison drug in many GLP‑1 trials, so it has gone head to head with almost every GLP‑1 on the market. Every GLP‑1 at its usual dose won on A1C, and every trial that reported weight favored the GLP‑1.^{[12][13][14][15][16][20]}

SUSTAIN 2 is the trial behind most “Januvia vs Ozempic” comparisons. It enrolled 1,225 adults on metformin, a thiazolidinedione or both. Over 56 weeks, semaglutide 1 mg lowered A1C by 1.6 points against 0.5 for sitagliptin, and weight by 6.1 kg against 1.9 kg.^[12] Ozempic’s label reports the same trial using a different statistical method, with weight changes of 5.5 kg against 1.7 kg. It also shows that 19% of people on sitagliptin needed rescue medication, against 2% on the 1 mg dose.^[3] PIONEER 3 found the same pattern with oral semaglutide, except at the 3 mg starter dose, which did not even match sitagliptin on A1C.^[13] Novo Nordisk funded the SUSTAIN and PIONEER trials.^[12][14]

The longest comparison was GRADE, a trial funded by the National Institutes of Health rather than a drug maker. It followed 5,047 people on metformin for five years after adding one of four drugs. Liraglutide kept A1C under 7% longer than sitagliptin: its rate of failure was 26.1 per 100 person-years against 38.1, the worst of the four drugs. People on liraglutide also lost more weight.^[17] On heart outcomes, the groups did not differ in major cardiac events. Liraglutide was linked to fewer of any cardiovascular events (hazard ratio 0.7) and sitagliptin to slightly more (1.2). The authors called these possible differences, not firm ones.^[18]

Tirzepatide has no published head-to-head trial against a DPP‑4 inhibitor in its U.S. label,^[4] so how much more it would do than Januvia has not been measured.

What you trade for the bigger effect

Januvia is easy to take, and GLP‑1 drugs are harder on the stomach. In SUSTAIN 2, nausea affected 18% of people on semaglutide against 7% on sitagliptin, and 8% to 10% stopped semaglutide because of side effects against 3% for sitagliptin.^[12] With liraglutide the gap was wider: 21% to 27% nausea against 5%.^[15] Which GLP‑1 tends to be hardest on the stomach is compared in which GLP-1 has the worst side effects.

Low blood sugar is not a reason to choose one over the other. The ADA lists neither class as causing it on its own.^[1] Some consumer pages say that combining the two raises the risk of lows. No trial has shown that. In GRADE, severe lows were rare on both: 1.0% on liraglutide and 0.7% on sitagliptin, against 2.2% on the sulfonylurea glimepiride.^[17] The risk comes from insulin and sulfonylureas, as covered in GLP-1 drugs and low blood sugar.

Both classes carry the same pancreatitis warning. Januvia’s label reports acute pancreatitis after approval, including fatal cases, and says the drug was never studied in people with a past episode. Ozempic’s label tells patients to stop if pancreatitis is suspected.^[2][3] The ADA groups GLP‑1 drugs, tirzepatide and DPP‑4 inhibitors together as incretin medicines to avoid after pancreatitis, while noting that causation for the DPP‑4 drugs has not been established.^[1] Taking both does not make the warning go away, and swapping one for the other does not get around it. What the GLP‑1 data show is in GLP-1 drugs, pancreatitis and gallbladder risk.

The switch: what happens when Januvia stops

The usual move is to stop the DPP‑4 inhibitor when the GLP‑1 starts. Three randomized trials tested that switch directly, and in all three blood sugar improved after the switch rather than slipping.

• LIRA-SWITCH. 407 people not controlled on sitagliptin and metformin either switched to liraglutide 1.8 mg or stayed on sitagliptin. Over 26 weeks, A1C fell 1.14 points against 0.54, and weight fell 3.31 kg against 1.64 kg. Nausea affected 21.8% after switching against 7.8%.^[19]
• The Pratley extension. After a year on sitagliptin, people moved to liraglutide lost a further 0.2 to 0.5 points of A1C and 1.6 to 2.5 kg. The share at an A1C under 7% rose from about 30% to about 50%. The nausea was “mostly transient.”^[8]
• PIONEER 7 extension. People moved from sitagliptin to oral semaglutide were more likely to reach an A1C under 7% than those who stayed on sitagliptin (52.6% against 28.6%) and lost more weight (2.4 kg against 0.9 kg). The difference in average A1C, 0.3 points, fell just short of statistical significance.^[21]

No label sets a taper or washout for sitagliptin, and none of these trials used one.^[2] The timing is a prescriber’s call, especially because a GLP‑1 starts at a low dose that is not meant to control blood sugar on its own. For several weeks, someone who stops Januvia on the same day may be on less treatment than before.

Check for a hidden DPP-4 inhibitor

Many people on a DPP‑4 inhibitor do not know it, because the drug is built into a combination pill. A GLP‑1 prescriber who looks for “Januvia” on a medication list can miss these:

Stopping one of these is not as simple as dropping a pill, because the partner drug may still be needed. Someone on Janumet may need to continue plain metformin, which pairs routinely with a GLP‑1, as covered in metformin and a GLP-1 together. Someone on Glyxambi or Steglujan may be taking the SGLT2 half for the heart or kidneys. That pairing has its own evidence, covered in SGLT2 inhibitors and a GLP-1 together.

If you take the GLP-1 for weight

No DPP‑4 inhibitor is approved for weight loss, and the ADA rates the class as weight-neutral.^[1] In Januvia’s own trials, weight on sitagliptin mostly matched weight on placebo or metformin alone.^[2] For someone with type 2 diabetes who starts Wegovy or Zepbound for weight, the Januvia adds nothing to the weight loss. Whether it adds anything to blood sugar is the question the ADA has already answered. Neither label addresses the combination.^[5][22]

Combinations like this are easy to start and hard to clean up. Each drug is often started by a different clinician, and nobody reviews the full list. A pharmacist’s review is the quickest fix, as set out in GLP-1 drugs and your other medications. Getting people to fill and stay on two diabetes drugs at once is its own problem, covered in why combination therapy fails in practice.

What to ask a prescriber

1. Is there a DPP‑4 inhibitor anywhere on my list? Check combination pills by name, not just Januvia.
2. Should it stop when the GLP‑1 starts, or later? Ask how blood sugar will be covered while the GLP‑1 dose is still low.
3. Does the partner drug continue? If the DPP‑4 is part of a combination pill, ask whether the metformin, SGLT2 or pioglitazone in it should be prescribed on its own.
4. Do my insulin or sulfonylurea doses need to change? These, not the DPP‑4 inhibitor, drive the risk of lows when a GLP‑1 is added.
5. I have had pancreatitis. Is any incretin drug right for me? The warning covers both classes.